An unusual hybrid renal tumour associating a diffuse large B-cell lymphoma and a clear cell renal cell carcinoma

Author(s):  
Claude Ghorra
Pathology ◽  
2020 ◽  
Vol 52 (6) ◽  
pp. 731-734
Author(s):  
Caroline Kurek ◽  
Stuart Ehsman ◽  
Timothy Brighton ◽  
Kathleen Young

2020 ◽  
pp. 106689692098163
Author(s):  
Alejandra Griselda Serrano ◽  
Boris Elsner ◽  
Maria Cecilia Cabral Lorenzo ◽  
Fabio Andres Morales Clavijo

Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma characterized by the selective growth of lymphoma cells within the lumina of vessels. The patient usually presents with nonspecific symptoms and a remarkable deterioration in performance status. The occurrence of synchronous IVLBCL and renal cell carcinoma (RCC) is extremely rare. A right kidney tumor was found in a 72-year-old man with a history of low back pain. The kidney was enlarged, with a tumor mass measuring 4.5 × 4 × 4 cm. Sections exhibited a RCC (clear cell type, nuclear grade I). Also an extensive tumor affecting capillaries and small veins was present, positive for CD45, CD20, BCL-2, and MUM1/IRF-4, consistent with IVLBCL. The lymphoma was circumscribed to the RCC. The final diagnosis was IVLBCL with a RCC as collision tumor. After that, with neurological findings, central nervous system compromise by lymphoma was made. The patient started a first cycle of chemotherapy, progressive deterioration of the sensorium, and positive blood cultures for Klebsiella pneumoniae and Escherichia coli. The patient died 8 days later of acute respiratory failure. No autopsy was done. IVLBCL is an aggressive and systemic disease characterized by massive proliferation of tumor cells without a known primary site. Clinical identification and histopathologic diagnosis are relevant issues in the therapeutic management of these lymphomas. Until now, only one case of IVLBCL coexisting with RCC has been reported. In this article, we report a second case of IVLBCL with RCC simultaneous, as an unusual collision tumor.


2018 ◽  
Vol 27 (6) ◽  
pp. 649-651
Author(s):  
Sotiris Sotiriou ◽  
Triantafyllia Koletsa ◽  
Ioannis Kostopoulos

2021 ◽  
Vol 11 ◽  
Author(s):  
Fafen Yang ◽  
Jingjie Zhao ◽  
Xiuzhuang Luo ◽  
Tong Li ◽  
Zechen Wang ◽  
...  

Although immune therapy can improve the treatment of clear cell renal cell carcinoma (ccRCC) significantly, there are still a large proportion of ccRCC patients who progress to metastasis. Targeting the pro-metastatic immune cell in the ccRCC microenvironment could provide a solution to this problem. In this study, B cells in ccRCC biopsies were identified by using scRNA-seq and flow cytometry. The findings indicated the presence of a pro-metastatic B cell type which could be further classified into 3 subpopulations, MARCH3, B2M and DTWD1, based on their large-scaled genetic profiles, rather than traditional Immature/Mature ones. Although all of the 3 subpopulations appeared to contribute to distant metastasis, B cell (B2M) was deemed to be the most essential. Moreover, STX16, CLASRP, ATIC, ACIN1 and SEMA4B, were genes found to be commonly up-regulated in the 3 subpopulations and this was correlated to a poor prognosis of ccRCC. Furthermore, the heterogeneity of plasma cells in ccRCC was also found to contribute to metastasis of the disease. This study offers potential novel therapeutic targets against distant metastasis of cancers, and can help to improve the therapeutic efficiency of ccRCC patients.


Sign in / Sign up

Export Citation Format

Share Document